Hutchmed reports publication of SACHI results in The Lancet

Hutchmed (HCM) reported that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib and osimertinib combination for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression on first-line EGFR tyrosine kinase inhibitor therapy. Savolitinib is an oral, potent and highly selective MET TKI being jointly developed by AstraZeneca (AZN) and Hutchmed and commercialized by AstraZeneca. Osimertinib is a third-generation, irreversible EGFR TKI. Based on interim data from SACHI, the savolitinib and osimertinib combination was granted regulatory approval in China in June 2025.